3,3′-Disubstituted 5,5′-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity
作者:Lian Xue、Da-Hua Shi、Jitendra R. Harjani、Fei Huang、Julia G. Beveridge、Tamir Dingjan、Kung Ban、Sarah Diab、Sandra Duffy、Leonardo Lucantoni、Sabine Fletcher、Francis C. K. Chiu、Scott Blundell、Katherine Ellis、Stuart A. Ralph、Grennady Wirjanata、Silvia Teguh、Rintis Noviyanti、Marina Chavchich、Darren Creek、Ric N. Price、Jutta Marfurt、Susan A. Charman、Matthew E. Cuellar、Jessica M. Strasser、Jayme L. Dahlin、Michael A. Walters、Michael D. Edstein、Vicky M. Avery、Jonathan B. Baell
DOI:10.1021/acs.jmedchem.8b01799
日期:2019.3.14
A series of 3,3'-disubstituted 5,5'-bi(1,2,4-triazine) derivatives was synthesized and screened against the erythrocytic stage of Plasmodium falciparum 3D7 line. The most potent dimer, 6k, with an IC50 (50% inhibitory concentration) of 0.008 μM, had high in vitro potency against P. falciparum lines resistant to chloroquine (W2, IC50 = 0.0047 ± 0.0011 μM) and artemisinin (MRA1240, IC50 = 0.0086 ± 0
合成了一系列 3,3'-二取代的 5,5'-双 (1,2,4-三嗪) 衍生物,并针对恶性疟原虫 3D7 系的红细胞期进行了筛选。最有效的二聚体 6k,IC50(50% 抑制浓度)为 0.008 μM,在体外对抗氯喹(W2,IC50 = 0.0047 ± 0.0011 μM)和青蒿素(MRA1240,IC50 = 0.0086 ± 0.0010 微米)。6k 的出色离体效力显示出对来自无并发症疟疾门诊患者血液的恶性疟原虫 (IC50 = 0.022-0.034 μM) 和间日疟原虫 (IC50 = 0.0093-0.031 μM) 的临床现场分离株。尽管 6k 在小鼠中被相对快速地清除,但它在 Peters 4 天试验中抑制了寄生虫血症,口服给药后的平均 ED50 值(50% 有效剂量)为 1.47 mg kg-1 day-1。